How the UK is setting new standards for genomic research and better health care
DRAGEN secondary analysis helps UK Biobank identify ~1.5 billion variants from a half-million genomes.
Accurate, comprehensive, efficient analysis
A suite of bioinformatics pipelines to process NGS data and maximize genomic discovery
Your email address is never shared with third parties.
Illumina DRAGEN (Dynamic Read Analysis for GENomics) secondary analysis enables labs of all sizes and disciplines to maximize the value of the genome with powerful, cutting-edge data analysis tools. DRAGEN secondary analysis provides accurate, comprehensive, and highly efficient bioinformatics with multiple deployment options, applications, and pipelines to meet your research needs.
Access DRAGEN secondary analysis via an on-premises server, cloud-based, or on-instrument solution. Multiple deployment options support your analysis needs without compromising accuracy, speed, or flexibility.
DRAGEN secondary analysis supports an extensive range of applications, providing comprehensive coverage for many experiment types in a single solution. Key applications include:
DRAGEN secondary analysis includes a versatile set of pipelines that can accept input data files and create output files at different stages of the pipelines.
The DRAGEN Iterative gVCF Genotyper (IGG) delivers a breakthrough solution for population-scale variant analysis, enabling fast, efficient aggregation and genotyping of small germline variants across large cohorts. Designed for speed, accuracy, and scalability, IGG supports incremental analysis so new sample batches can be added without reprocessing the entire dataset.
In our hands, using DRAGEN [secondary] analysis, we have realized cost savings of approximately 50%. In terms of computational time, it’s almost double the speed compared to the manual method.
From genetic diseases to oncology to pharmacogenomics and more, DRAGEN secondary analysis can help labs in any field scale up NGS operations and make game-changing genomic analysis a reality.
DRAGEN secondary analysis helps UK Biobank identify ~1.5 billion variants from a half-million genomes.
DRAGEN secondary analysis helps Cardio-CARE cut their data-processing time, reduce their data storage footprint by 80%, and rapidly analyze WGS data for a study with 9000+ participants.
The DRAGEN PGx pipeline enables genotyping of 20 genes related to drug metabolism to support new drug development.
The evolution of the multigenome mapping methodology using pangenome references, showing significant accuracy improvements.
Discover how DRAGEN somatic indel methods enabled high accuracy variant calling in the NCTR indel calling from Oncopanel Sequencing Data Challenge.
Discover how multi-region joint detection (MRJD) addresses the challenge of de novo germline variant calling in difficult to map regions of the genome.
DRAGEN v4.4 is here with powerful innovations for genomic and multiomic analysis.
This release introduces new oncology applications for Heme WGS, Solid WGS tumor-normal, and a streamlined pipeline for Minimal Residual Disease (MRD). It also delivers optimized secondary analysis for the latest assays and major accuracy gains in germline and somatic pipelines, including improved structural variant calling.
Watch the on-demand webinar to explore all the new features and see how DRAGEN v4.4 accelerates your journey from samples to insights.
View more details about DRAGEN secondary analysis features, learn how to order, and find product documentation. You can also speak to a specialist to get your questions answered.
Your email address is never shared with third parties.
References